Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Recursion probably needs to advance 5-10 ...

Recursion's share price continues to be volatile, despite its pipeline maturing and the injection of significant cash through its merger with Exscientia. While early clinical data has been marginal, ...

SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...

Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs Platform will ...

The artificial intelligence (AI) revolution continues to tout developing drugs faster and at lower cost, but are we there yet? On October 2nd, the FDA cleared an investigational new drug (IND) ...

米カリフォルニアスタートアップ「Recursion, Inc（リカージョン）」（本社：カリフォルニア州ロサンゼルス、代表取締役：田島慎也 、Jeffry Alvarado、以下当社）は、オンラインプログラミング学習サービス「Recursion」にて、2020年8月7日より、「コンピュータ ...

技術進化が著しい現代において、バックエンドエンジニアの採用は企業にとっての大きな挑戦となっています。この課題に応えるべく、Recursion, Inc（共同創業者：田島慎也、Jeffry Alvarado、本社：アメリカカリフォルニア州）は、Recursion転職を立ち上げました。